Replies to post #386747 on Amarin Corp Plc (AMRN)

[CaptBeer]

They never talk about studies in which they are not the sponsor.

[Whalatane]

Bio. MITIGATE is high risk for AMRN
I’ll explain soon
MITIGATE is an independent Kaiser run trial . AMRN supplies the Vascepa but Kaiser controls everything… trial design , when to publish data etc

Kaiser IMHO is not totally sold on the R-IT data .
I had an angiogram at Kaiser several yrs ago and remember the interventionist Cardiologist doing the procedure debating my regular Cardiologist on wether Vascepa really provided much benefit .

The interventionist argued for V based on reducing inflammation.
My regular Cardiologist wanted another trial to confirm the R-IT data

So MITIGATE is really 2 trials for Kaiser
One to see if V reduces Covid hospitalization
The other CV part … to see if the event lines start to separate as they did in prior MI US R-IT .

Kaiser will have the Top Line Covid data in the first wk of Sept … and detailed CV data early in 2023

I’m not predicting this … but if both fail
AMRN trades under a $1
If both succeed … showing clinical significance .. we trade over $3
JMO
Kiwi